The Celltiter-Glo process uses a 2D or 3D assay of the cell line of interest. For a general 2D assay, the cells are plated, allowed to attach overnight, and treated with various concentrations of the test compounds (typically between a six to eight dose range,) as well as vehicle and media only controls. Cell viability is assessed through the luminescent ATP assay, Celltiter-Glo. The reagent lyses the remaining live cells and creates a luminescence which can be read using a plate reader.
Researchers in Visikol’s Pharmacology and Drug Discovery division are skilled in toxicity assessment and screening in 2D and 3D cellular based assays. The graph’s shown below are the results of two viability and cytotoxicity assessments using A549, lung carcinoma, and HCT-116, colorectal carcinoma, cell lines. Each cell line was treated in triplicate with three different therapeutics separately, Chlorpromazine, Diclofenac, and Paclitaxel. Chlorpromazine is a medicine for schizophrenia, Diclofenac is an anti-inflammatory, and Paclitaxel is a chemotherapy medication. These are all very different therapeutics, each with cytotoxic effects on cells. The cells were seeded, dosed after twenty-four hours with seven doses including vehicle and media only controls, and the Celltiter-Glo assay was performed after seventy-two hours of treatment. Dose, D1, have been the highest concentration and decreasing with each dose. The luminescence value corresponds with the number of live cells at the end of seventy-two hours.